🇺🇸

US SEC Filing Intelligence

· daily

Global High-Priority Regulatory Events — March 20, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include ongoing insolvency proceedings in Indian firms (e.g., AGS Transact, Quadrant Televentures), promoter share acquisitions signaling conviction (DCM Shriram), SPAC mergers with high redemptions (Pelican Acquisition), biotech trial successes (Artelo), and M&A/takeover activity (NSA, Embecta, CoinShares). Period-over-period trends show robust revenue growth in 12/50 filings averaging +90% YoY (e.g., Firefly +163%, Aeva +99%, Belpointe +244%), but persistent net losses widening in 8 cases (avg +50% YoY) amid margin volatility and high R&D/debt costs; gross margins expanded notably in QIAGEN (+1,330 bps to 62.2%). Insider/promoter activity is bullish in 4 Indian firms with +5-10% stake increases, while pledges/encumbrances flag leverage risks. Forward-looking catalysts cluster in Q1-Q2 2026: merger closings, CoC meetings, and trial escalations. Portfolio implications favor monitoring biotech/SPAC turnarounds and avoiding insolvency-exposed names, with alpha in revenue accelerators trading below peers.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 20, 2026

A surge of 5 new S-1 filings on March 20, 2026, highlights a robust IPO pipeline across crypto ETFs, biotech, consumer tech, quantum computing M&A, nuclear energy, and early-stage tech, with the 6th providing context on governance evolution. Positive sentiments dominate in biotech (Artelo) and quantum (IonQ merger), driven by superior trial outcomes (e.g., Artelo's 6.38% weight gain vs -5.42% placebo) and strategic vertical integration, while mixed/neutral tones prevail elsewhere amid volatility risks and competition. No broad revenue/margin period-over-period declines reported, but GoPro notes recent market share losses contrasting Artelo's strong Phase 2a efficacy metrics. Key developments include Artelo's dose escalation to 1,300 micrograms and IonQ's $15/share + stock merger with SkyWater, signaling sector consolidation. Portfolio-level patterns show high equity comp in pre-IPO firms (X-energy CEO $10.5M, 88% stock awards), indicating management alignment, with implications for near-term listings on Nasdaq/NYSE boosting liquidity and alpha in high-volatility names.

6 high priority 6 total filings
· daily

US Earnings Financial Results SEC Filings — March 20, 2026

Across 50 10-K and 10-Q filings from March 20, 2026, primarily FY2025 results, a dominant mixed sentiment prevails with 70% of named companies showing revenue growth averaging 40% YoY in high-growth sectors like aerospace (Firefly +163%), tech (Snowflake +29%, Aeva +99%), and retail (Dollar General +5.2%, Victoria's Secret +5%) but persistent net losses widening in 60% of cases due to high opEx/R&D and impairments. SPACs (e.g., Pelican, Bluerock, Jackson) represent ~20% of filings, holding intact trust accounts with interest income driving modest profits amid pre-merger deficits. BDC/investment vehicles (11 filings) expanded assets/portfolios 50-80% YoY with investment income up 50-110%, though yields compressed 100bps to 9.1% on average, signaling rate sensitivity. ABS servicing compliance in 15+ unknown filings remains routine/neutral with no deficiencies, focusing on standard timeframes (2-90 days). Capital allocation leans toward financing inflows ($100M+ in Aeva, Firefly) over dividends/buybacks, with outliers like AutoZone's $742M buybacks. Portfolio-level trends highlight growth resilience but profitability challenges, implying near-term catalysts from guidance-embedded EBITDA targets (Wellgistics to 2026) and product launches (Milestone PSVT in 2026).

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 20, 2026

Across 50 DEF 14A proxy statements, a dominant theme is robust 2025 performance with 18 companies reporting YoY revenue growth averaging 10%+ (e.g., Ameriprise +6% rev/$18.2B, Goldman +9%/$58.3B, Inspire +14%/$912M, Eli Lilly $65.2B), strong EPS expansions (Goldman +27% to $51.32, Ameriprise +12% to $39.34), and margin improvements (Latham +320bps gross margins, Pentair +170bps adj ROS), though 6 showed declines like Avalon net income -76% YoY. Positive sentiment prevails in 22 filings (44%), mixed/neutral in 28, with no explicit insider selling but high ownership concentrations signaling alignment (e.g., Preformed Line 33% insiders). Capital allocation favors shareholders via dividend hikes (Ameriprise 21st consecutive +20% returns, Penske $182M buybacks/1.8% shares), buybacks, and LTIPs tied to CAGR targets. Portfolio-level trends highlight financials/healthcare outperformance vs industrials mixed results, with pay-for-performance evident (Cogent CEO 152% AWR target payout). AGMs cluster April 29-May 13, 2026 as key catalysts for comp votes, auditor ratifications, and equity plan amendments. Market implications: Buy dips in high-performers pre-vote, monitor pay scrutiny in decliners.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 20, 2026

Across 38 SEC filings on US executive and director changes dated March 20, 2026, the dominant theme is high C-suite and board turnover with 70% neutral sentiment, including 18 resignations/retirements (mostly voluntary, no disagreements cited except one), 12 appointments/promotions of experienced executives, and 5 salary/bonus adjustments signaling retention efforts. No widespread period-over-period financial deterioration evident, but isolated YoY EPS gains (e.g., Nu Skin) and equity grants contrast with severances totaling $810k+ across cases like Aeries ($265k), CleanCore ($500k), reAlpha ($46k). Biotech/pharma (Aquestive, AN2, Iovance) shows positive hires amid FDA catalysts, while tech (SMCI, Rigetti, Roblox) mixes promotions with legal risks and board exits. Portfolio-level pattern: 15 CFO/CIO changes suggest transition risks in growth sectors; insider conviction mixed with promotions (e.g., Kite Realty CFO) but concerns from disputes (APHP). Implications: Bullish for experienced hires in REITs/fintech, bearish for legal overhangs; watch Q2 2026 AGMs and successor searches for volatility.

38 high priority 38 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 20, 2026

Across 41 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is acute small-cap distress with 13 companies (e.g., GoHealth, Quince Therapeutics, MaxCyte, NextNRG, Ernexa, Tivic, Heritage/IPST, Faraday Future, Tela Bio, Alzamend Neuro) receiving Nasdaq deficiency notices for bid price < $1.00 over 30 days, MVLS/equity shortfalls, or audit committee issues, risking delisting by Sep 2026; Zynex confirmed Ch11 reorganization with equity cancellation (no recovery for 30.8M shares). Period-over-period trends show revenue declines (Beasley Broadcast -8.7% CAGR FY23-25 to $206M, audio -11.8%), but some improvements like Spruce Biosciences net loss -26% YoY to $39M FY25 and Embecta/Prestige accretive M&A. Forward-looking catalysts cluster in H1-Q3 2026: merger closings (KORE $9.25/share, Dillard's), compliance deadlines (180 days to Sep), Zynex emergence by Mar31; financings (TG Therapeutics $750M term loan, Fortive $2B revolver) signal liquidity support amid distress. Capital allocation leans defensive (debt paydowns, no dividends/buybacks noted except Fair Isaac $1B notes for repurchases), with insider reliance (Perfect Moment $5M chairman loans extended). Portfolio-level: Biotech/healthcare outliers in delisting risks (8/13), while consumer/energy M&A bucks trend; implications include short opportunities in non-compliant microcaps, long setups in turnaround financings/M&A.

41 high priority 41 total filings
· daily

US SEC Trading Suspension Halt Orders — March 20, 2026

A cluster of 11 small-cap companies, predominantly in biotech and healthcare (7/11), received Nasdaq deficiency notices between March 16-20, 2026, signaling acute distress in microcap listings with uniformly negative sentiment and high materiality (avg 9.3/10). Dominant theme: 9/11 failed minimum bid price requirement (<$1.00 for 30 consecutive business days), alongside MVLS shortfalls (GoHealth <$35M, Quince <$50M), low stockholders' equity (Alzamend $2.2M vs $2.5M min), and one audit committee violation (Lifeward <3 members). No enriched period-over-period financial improvements noted; implied QoQ stock price declines drove all bid failures over recent 30-day windows. Compliance periods standardize at 180 days to ~September 14-16, 2026, creating a portfolio-level delisting cliff, with 2 firms (Ernexa, Heritage) ineligible due to recent reverse splits, heightening urgency via hearings. Absent positive insider activity, capital allocation, or operational metrics, this wave underscores small-cap weakness amid potential funding droughts, risking mass OTC transfers, liquidity evaporation, and 20-50% further drawdowns.

11 high priority 11 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 20, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical development: Zynex Inc.'s Chapter 11 reorganization plan confirmation on March 19, 2026, marking the culmination of proceedings initiated December 15, 2025, with emergence expected by March 31, 2026. All 30,781,021 existing common shares are cancelled with zero recovery for equity holders, transferring 100% ownership (approximately 1,000 new shares) to the Plan Sponsor and providing DIP Lenders $10M in takeback debt. No period-over-period financial trends are detailed in the filing, but the Nasdaq delisting (effective February 2, 2026) and OTC trading as ZYXIQ underscore speculative risks and total equity wipeout. Market implications include complete shareholder value destruction, heightened volatility in OTC trading, and a bearish sentiment (rated negative, materiality 10/10). Portfolio-level patterns are limited to this filing, but it exemplifies ongoing corporate insolvency pressures in the medical device sector, with no insider activity, capital allocation, or forward guidance beyond plan effectiveness noted.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 20, 2026

Across 38 SEC 8-K filings on USA Board Room Changes from March 16-20, 2026, the dominant theme is high executive and director turnover, with 24 resignations/retirements (mostly neutral voluntary exits citing no disagreements) versus 14 appointments/promotions, signaling routine board refreshes amid stable operations but potential leadership gaps in tech, biotech, and financials. Positive hires bring deep sector expertise (e.g., ex-Coinbase CFO at Streamex, Dycom ex-CEO at Centuri), while negatives include a director resignation over financial planning disputes at American Picture House and a criminal indictment impacting Super Micro executives. No uniform period-over-period financial trends emerge as filings focus on governance, but isolated signals like Nu Skin's interim CFO crediting YoY EPS gains from cost cuts and BranchOut's retroactive salary hikes post-growth highlight pockets of operational strength. Materiality skews high (avg 6/10) for CEO/CFO shifts (12 cases), implying short-term execution risks but long-term strategic upgrades. Portfolio-level pattern: neutral sentiment in 70% of filings suggests low disruption risk, but watch clustered director retirements ahead of 2026 AGMs for governance evolution. Market implication: opportunities in experienced hire turnarounds, risks in unresolved successions.

38 high priority 38 total filings
· daily

US Merger & Acquisition SEC Filings — March 20, 2026

The 12 filings reveal a surge in SPAC activity with 6 new IPOs or post-IPO events (SUMA, BHAV, Muzero, Fifth Era, Cayson, Pelican) and de-SPAC mergers advancing rapidly, including Pelican-Greenland closing March 24 and Nexstar's completed TEGNA acquisition on March 19, signaling robust M&A momentum in a tight window (March 12-24). Period-over-period trends show outlier strength in Merlin Labs (Inflection Point target) with 515% YoY revenue growth to $7.6M despite 35% wider net losses to $74.8M from opex and warrant surges, while B&G Foods' $110M Del Monte acquisition projects immediate EPS accretion ($0.08-0.12) at 5.5x EBITDA multiple. High redemptions (63% or 7.56M shares, $77.7M) in Pelican highlight cash drain risks in de-SPACs, contrasting full over-allotment exercises in SUMA (+2.25M units) and BHAV's $100M IPO. Media sector consolidation via Nexstar-TEGNA and TEGNA governance tweaks underscores strategic M&A, with neutral governance shifts in Horizon Quantum and Solaris financing potential Genco buy. Overall, bullish SPAC pipeline but mixed sentiment from redemptions and loss trends implies selective opportunities pre-close.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 20, 2026

Overnight SEC filings reveal robust M&A and SPAC activity, with healthcare deals like Prestige's $1.045B Breathe Right acquisition and Embecta's £150M Owen Mumford buyout signaling sector consolidation, while SPAC mergers (CoinShares, Pelican/Greenland, Einride/Legato) advance amid heavy redemptions (Pelican 63%). Revenue growth dominates period comparisons across 12/50 filings, averaging +80% YoY (e.g., Firefly +163%, Aeva +99%, Cellectis +62%), but 8/12 show widening net losses (avg +40%) due to R&D/opex surges and yield compression in BDCs (avg -0.9%). Margin expansions stand out (QIAGEN gross +1,330bps to 62.2%), contrasting compression elsewhere; activist pressure mounts on Lululemon (Wilson 8.4% stake, criticizing flat FY2026 outlook). Capital allocation leans toward buybacks (News Corp $1B program) and financing (Firefly $1.3B inflows), with forward catalysts clustered in late March (merger closings) and April (earnings, meetings). Portfolio-level: Tech/AI/space names outperform on revenue but lag on profitability; BDCs grow assets +72-83% but face yield/margin erosion. Actionable: Favor accretive M&A targets, monitor SPAC post-merger liquidity.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (though diverse with funds, biotechs, REITs), proxy statements dominate (24/50, neutral sentiment) signaling robust governance ahead of clustered April-May 2026 annual meetings. Financial reporters (10-K/8-K, 18/50) show mixed YoY revenue growth averaging +25% (e.g., Vericel +20% CAGR, Satellogic +38%, electroCore +27%) but persistent net losses narrowing in 7/12 cases (e.g., SentinelOne op inc positive swing). Margin trends mixed with expansions (Signet adj op inc +3.4% FY, Vericel gross 74%) offset by compressions (Signet Q4 -60bps). Capital allocation leans positive: dividend hikes (Signet +17% to $0.35/sh, Modiv $0.10/mth), buybacks (Mount Logan $10M program), accretive M&A (Mount Logan +30% FRE). Forward guidance cautious (Signet FY27 SSS -1.25% to +2.5%) amid Q4 softness, but clinical catalysts in biotechs. Portfolio-level: Stable dividends vs reinvestment, low insider trading signals conviction, watch proxy outcomes and Q1 earnings for consumer resilience.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly including transportation, construction, and adjacent sectors amid mixed data), overarching themes include robust revenue growth in transportation leaders like FedEx (+8% YoY Q3 to $24B) and strategic pivots (UPS prioritizing high-value volume), contrasted by widening losses in biotechs (Eledon +26% net loss YoY) and operational declines (Gemini trading volume -30% QoQ). Period-over-period trends show 12/50 companies with double-digit YoY revenue gains averaging +45% (e.g., argenx +90%, Eton +83% Q4), but 8 with margin compression or expense surges (avg +30-40% OpEx); adjusted EPS grew in outperformers like Darden (+5.4%) and FedEx (+16.4%). Capital allocation favors shareholder returns with 15+ dividend declarations (e.g., Global Net Lease prefs at coupon rates) and buybacks (GrowGen $10M, Darden $127M Q3). Proxy season dominates with 20+ DEF/DEFA14A filings clustering AGMs in May 2026, featuring governance votes and comp approvals. Forward-looking signals positive: FedEx raised FY26 guidance (rev 6-6.5%, EPS $19.30-20.10), Eton >$110M 2026 rev; risks from earnings delays (Armata) and trial postponements (Catalyst to May 18). Portfolio implication: overweight transportation (FedEx/UPS resilience), monitor biotech turnarounds, capitalize on May catalysts.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 19, 2026

S&P 500 Energy sector filings from March 19, 2026, reveal a mix of proactive capital market access and shareholder governance activities, with Occidental Petroleum (OXY) dominating positive narratives through robust 2025 performance highlights including $10.5B operating cash flow, $4.3B free cash flow before working capital, $575M cost reductions, record production, and safety TRIR of 0.07 despite YoY challenging commodity prices. Cheniere Energy (LNG) signals strong liquidity via $1.75B senior notes issuance (5.200% due 2036, 6.000% due 2056), with registration rights underscoring structured debt management. Valero Energy (VLO) filings focus on standard proxy processes for its May 7 AGM, showing neutral sentiment and no financial trends disclosed. Aggregated period-over-period insights from OXY highlight debt reduction ($4B direct + $7B from OxyChem divestiture), resource base expansion to 16.5B BOE (up from 8B in 2015, +106%), and dividend growth (8%+ quarterly hike, +44% since 2023 CrownRock deal announcement), painting a picture of resilient capital allocation amid sector headwinds. Proxy season activation across OXY and VLO sets up near-term catalysts, while LNG's financing bolsters balance sheet for potential growth. No insider trading, guidance changes, or M&A details emerged, but positive sentiments from key filings (LNG/OXY) outpace neutrals, implying sector stability with pockets of outperformance.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 19, 2026

Across 50 diverse SEC filings (despite 'S&P 500 Financials' stream label, spanning industrials, biotech, tech, mining, and limited true financials like BDCs/REITs), sentiment skews mixed with 14/50 positive, 16 mixed, and robust YoY revenue growth averaging +35% in 18 reporting companies (e.g., Micron +196%, Cardinal +45%, SUNation +26%) offset by declines in 6 (e.g., Solo Brands -30%, DarioHealth -17%). EBITDA/margin expansions prevalent in 12 cases (e.g., SUNation + to $2.5M, Aebi Schmidt Q4 +31%), but net losses widened in 10 biotechs/miners amid opex surges; cash strengthened in 15 (avg +40% YoY where trended). Capital allocation favors dividends (8 declarations steady, e.g., Chicago Atlantic BDC $0.34/share x6 quarters) and buybacks/debt paydowns (News Corp $1B program, SUNation debt -57%). M&A/SPAC activity high (RYVYL 99% merger support, Vine Hill EGM), proxy/AGMs cluster Q2 2026. Portfolio trends signal resilient growth amid costs, with BDC/REIT stability contrasting volatile small caps; actionable now: favor high-conviction growth like Micron/Accenture, monitor merger catalysts.

23 high priority 27 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 19, 2026

Across 50 US SEC filings dated March 19, 2026, dominant themes include aggressive capital raising via equity/debt offerings (e.g., SAB, Reviva, Humacyte, Wolfspeed), M&A and SPAC extensions/amendments (MLCI acquisition, Pyrophyte to Apr 2027, Movano-Corvex merger), credit facility amendments tied to pending mergers (AES, Dayton Power), and board/governance changes (appointments at CVS, RGA, resignations at TripAdvisor, LiveRamp). Period-over-period trends reveal revenue pressures in hospitality (RCI Hospitality -5.5% YoY to $279.4M, Bombshells -29.2% YoY; Ashford pro forma -1.5% YoY to $1.15B) but balance sheet improvements via asset sales/debt paydowns (Ashford $56.8M sale, DevvStream $5.9M net debt reduction). Positive catalysts include accretive deals (Collegium AZSTARYS $650M for >$50M H2 2026 revenue, MLCI +30% FRE), debt refinancings (Wolfspeed $475.9M lower-cost notes), and JV formations (Horizon $100M). Financial stress signals in cannabis (Cannabist forbearance to Mar 25) and microcaps (Scorpius $248K notes) contrast with biotech fundraising for trials (SAB-142, brilaroxazine). Portfolio-level: 12/50 filings show financing stress (debt/notes/forbearance), but 8 accretive M&A/JVs signal consolidation; watch Q2/Q3 closings for alpha.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 19, 2026

Across 20 S&P 500 Technology sector filings dated March 19, 2026, dominant themes include explosive revenue growth in semiconductors (Micron +196% YoY Q2 revenue to $23.9B) contrasted with modest IT services expansion (Accenture +8.3% YoY Q2 revenue) and revenue declines in niche tech (MultiSensor AI -25% YoY, Intuitive Machines -7.9% YoY), highlighting divergent performance amid cost discipline reducing losses portfolio-wide (e.g., Mustang Bio net loss -88% YoY, MultiSensor AI -46% YoY). Margin expansions in high-growth names like Micron (gross margin +499% YoY) offset compressions elsewhere (Planet Labs Q4 gross margin -800bps YoY to 54%), with positive forward guidance from Accenture (FY26 revenue 3-5% LC growth, raised) and Planet Labs (FY27 revenue $415-440M). Capital allocation leans shareholder-friendly via repurchases (Accenture treasury shares cost up to $11B), dividends (Palmer Square supplemental $0.01/share, Community Bancorp $0.25/share), and M&A (Intuitive Machines $800M acquisitions, dMY Squared quantum merger). Space tech shows momentum with contract wins and backlog surges (Planet RPOs +106% YoY to $852M, Intuitive backlog $943M), while neutral proxy filings signal routine governance. Portfolio-level trends point to 6/10 filings with revenue growth averaging +70% YoY in outperformers, but mixed sentiment (5 positive, 5 mixed) underscores selective opportunities in semis and space over softening software/services. Overall, bullish for high-conviction growth names with raised guidance, bearish for revenue decliners despite loss narrowing.

10 high priority 10 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 19, 2026

Across 21 NASDAQ-100 related filings from March 19, 2026, dominant themes include explosive growth in semiconductors (Micron +196% YoY revenue) and AI/space sectors (Intuitive Machines $900M-$1B 2026 guidance), contrasted by revenue declines in sensor/AI holdings (MultiSensor -25% YoY) and persistent losses in metals/biotech (Lifezone net loss -$14.1M). Period-over-period trends show 7/21 companies with revenue growth >10% YoY (avg +150%), margin expansions in top performers (Micron gross margin +499% YoY), and widespread loss narrowing (Mustang Bio -88%, MultiSensor -46%). Balance sheets strengthened via financing (Intuitive Machines cash +181% to $582.6M, MultiSensor +459% to $24.4M), with capital allocation favoring debt reduction (Micron LT debt -32%) and dividends (Community Bancorp $0.25/share). Procedural filings (proxies, mergers) signal governance stability but low materiality. Portfolio-level, tech/AI outliers drive bullish sentiment (avg materiality 7/10), implying overweight in semis/space amid positive guidance and backlogs, while monitoring cash burn in pre-revenue explorers.

12 high priority 9 medium 21 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 19, 2026

Across 50 filings from the USA Dow Jones 30 intelligence stream (primarily smaller caps and blue-chips like UPS, CVS), a mixed sentiment prevails with 12/50 showing positive revenue/EBITDA growth (avg +40% YoY where reported, e.g., SOLV Energy +80% Q4 rev), contrasted by 8 cases of declines (avg -20% YoY rev/ARR) and debt stresses; healthcare/services outperform with 4/6 reporting +20%+ rev growth and margin expansion (e.g., Vericel 74% gross margin, +33% Adj EBITDA). Proxy statements dominate (14/50, mostly neutral, materiality 5/10 avg) signaling annual meeting season with May catalysts, while capital allocation leans defensive via dividends (6 declarations totaling ~$0.40-0.46/share quarterly). M&A activity peaks with 5 pending votes (RYVYL merger 99% in favor but adjourned; Vine Hill SPAC venue change) and deals like Aveanna's $175.5M acquisition. No widespread insider trading signals, but major holders noted in funds (GAMCO 9-10%). Forward guidance bullish for 7 cos (e.g., SOLV $3.72-3.82B 2026 rev +50% implied), building Q2 2026 catalysts; portfolio trend: growth outliers in space/health vs stressed balance sheets elsewhere.

29 high priority 21 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 19, 2026

Across 50 SEC filings for March 19, 2026, key themes include mixed FY2025 financial results with explosive growth in semiconductors (Micron +196% YoY revenue) and biotech (argenx +90% sales), contrasted by declines in digital health (DarioHealth -17% revenue) and energy (Equinor -2.5% revenues). Airlines showed resilience (Republic Airways +13.7% revenue, +32.9% Adj EBITDA), solar outperformed (SUNation +77% Q4 revenue beat), while mining had production gains but cost pressures (Gold Resource + AuEq oz YoY). Capital allocation remains shareholder-friendly with dividends declared (Modiv, Global Net Lease) and News Corp's $1B buyback program ongoing. SPAC extensions (Pyrophyte, Artius II, Rice Acq) signal prolonged deal hunts amid no combinations; RYVYL merger nears approval with 99% yes votes. Routine ABS 10-K compliance across 20+ filings indicates stable servicing with no material issues. Portfolio trend: 7/15 high-materiality firms beat revenue expectations YoY, but 5 saw cash declines; forward catalysts cluster late March (earnings, votes). Implications: Favor growth sectors like semis/biotech; monitor energy/health stress and merger closes for near-term alpha.

37 high priority 13 medium 50 total filings